TrademarkIQ iconTrademarkIQ
Back to search
Official data from USPTO

DELIVEREX

Did you know this trademark is already registered in United States?

Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.

Active USPTO registrationType: WordOffice: US

Quick snapshot

DELIVEREX

ST13

US500000079282940

Class

5, 44

Filing

79282940

Registration

6405652

Risk and opportunity diagnosis

Executive reading for naming, filing, and monitoring decisions.

Attention: there is active risk

USPTO status

Active USPTO registration

Case type

Application and registration

Recorded events

37

Latest update

07/06/2026

Classification

Registered

Trademark type

Word

Nice classes

5, 44

Filing date

01/31/2020

Registration date

07/06/2021

Expiration date

-

Recommended action

Perform a full collision analysis and validate classes before any filing or trademark investment.

Next step

These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.

Complete case details

Structured fields from the responsible authority and the official record.

Status date

07/06/2021

Last transaction

07/06/2026

Responsible office

United States Patent and Trademark Office

Status code

700

Official register

Principal Register

Drawing code

4

Owner type

24

Owner location

GB

Examiner

PAYABYAB, EDWARD TAN

Law office

O10

Current location

PUBLICATION AND ISSUE SECTION

Holders and representatives

Holders

Evox Therapeutics Limited

Representatives

Bryce J. Maynard Buchanan Ingersoll & Rooney PC

Technical classification

Nice Classes

Class 5Class 44

Vienna Codes

No Vienna codes available.

Goods and services

Class 5

Pharmaceutical preparations and substances for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, a drug delivery system comprising genetically engineered and purified exosomes in the form of a liquid solution and lyophilised preparation for therapeutic use in the nature of treatment of for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; pharmaceutical preparations, namely, exosomes to deliver protein for genetic therapy; Medicine for treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; biological preparations for the treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies such as mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy; mixed biological preparations for the prevention and treatment of infectious diseases; EV-based nucleic acid therapeutics in the nature of pharmaceuticals, medicines, biologics, biotherapeutics, biosimilars, and therapeutics for the prevention and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, genetic diseases, rare diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids for use in disease detection; diagnostic kits comprised of medical diagnostic reagents and assays that test for the presence of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strains and tears, ligament strains and tears, muscle atrophy, and muscular dystrophy

Class 44

Medical services; medical and pharmaceutical consultancy; medical services relating to the diagnosis and treatment of persons; medical analysis service relating to the diagnosis and treatment of persons provided by medical laboratories; medical analysis and examinations for the diagnosis of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint strain and tears, ligament strain and tears, muscle atrophy, muscular dystrophy, neuromuscular diseases, neurological disorders, neurodegenerative disorders, inflammatory disorders, infectious diseases, rare diseases, genetic diseases, in-born errors of metabolism, lysosomal storage disorders and urea cycle disorders; medical treatment services in the field of biotherapeutics for the treatment of infectious diseases, cancer, neurological disorders, neurodegenerative disorders, inflammatory disorders, rare diseases, genetic and metabolic disorders; medical screening; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of viral and bacterial based infections and diseases; medical monitoring, testing, inspection and analysis services relating to the diagnosis and treatment of cancer, diabetes, obesity, metabolic syndrome, dementia, and other aging associated pathologies in the nature of mitochondrial disease, joint and ligament strains and tears, muscle atrophy, muscular dystrophy

Publications

History of USPTO decisions and trademark events.

37 publications found

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

07/06/2026

NREP

NEW REPRESENTATIVE AT IB RECEIVED

12/04/2021

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

11/23/2021

FICS

FINAL DISPOSITION NOTICE SENT TO IB

11/01/2021

FIMP

FINAL DISPOSITION PROCESSED

11/01/2021

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

10/06/2021

R.PR

REGISTERED-PRINCIPAL REGISTER

07/06/2021

LIME

LIMITATION FROM THE IB EXAMINED AND ENTERED

05/04/2021

LIMG

LIMITATION OF GOODS RECEIVED FROM IB

05/01/2021

NPUB

OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED

04/20/2021

PUBO

PUBLISHED FOR OPPOSITION

04/20/2021

GPNX

NOTIFICATION PROCESSED BY IB

04/18/2021

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

03/31/2021

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

03/31/2021

NONP

NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED

03/31/2021

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

03/13/2021

XAEC

EXAMINER'S AMENDMENT ENTERED

03/13/2021

GNEN

NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED

03/13/2021

GNEA

EXAMINERS AMENDMENT E-MAILED

03/13/2021

CNEA

EXAMINERS AMENDMENT -WRITTEN

03/13/2021

GNS3

NOTIFICATION OF LETTER OF SUSPENSION E-MAILED

03/06/2021

GNSL

LETTER OF SUSPENSION E-MAILED

03/06/2021

CNSL

SUSPENSION LETTER WRITTEN

03/06/2021

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

01/28/2021

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

01/28/2021

ALIE

ASSIGNED TO LIE

01/27/2021

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

10/16/2020

NREP

NEW REPRESENTATIVE AT IB RECEIVED

07/30/2020

RFNT

REFUSAL PROCESSED BY IB

05/29/2020

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

05/14/2020

RFRR

REFUSAL PROCESSED BY MPU

05/14/2020

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

04/30/2020

CNRT

NON-FINAL ACTION WRITTEN

04/29/2020

DOCK

ASSIGNED TO EXAMINER

04/20/2020

MAFR

APPLICATION FILING RECEIPT MAILED

04/17/2020

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

04/13/2020

REPR

SN ASSIGNED FOR SECT 66A APPL FROM IB

04/09/2020

Continuous trademark protection

Get notified about every new filing that threatens DELIVEREX or your mark.

Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.